Abiopharma

New Form 424B3 - AlphaTON Capital Corp Filed: 2025-10-22 AccNo: 0001171843-25-006583 Size: 22 KB

(10% Negative) Alkermes plc. (ALKS) Announces Business Combination

Akari Therapeutics Announces Launch of CEO Corner Platform

New Form SC 14D9/A - Tourmaline Bio, Inc. Filed: 2025-10-22 AccNo: 0001104659-25-101420 Size: 15 KB

Sellas Life Sciences - SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

(75% Positive) NURIX THERAPEUTICS, INC. (NRIX) Announces Enrollment Update for medicines Due to Patient Enrollment Issues, Regulatory Process, Safety Review

(99% Neutral) IMAGENEBIO, INC. (IKNA) Announces New Board Appointment

- Femasys Announces Initiation of Post-Market Surveillance Study forFemBloc® Permanent Birth Control in Europe

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor“What This Means” Segment

(99% Neutral) Jazz Pharmaceuticals plc (JAZZ) Announces Clinical Development Update

New Form 6-K - AlphaTON Capital Corp Filed: 2025-10-22 AccNo: 0001171843-25-006582 Size: 10 KB

(99% Neutral) ONCOTELIC THERAPEUTICS, INC. (OTLC) Files Form 8-K

(10% Negative) Summit Therapeutics Inc. (SMMT) Announces Delay in Investors Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

New Form 6-K - GSK plc Filed: 2025-10-22 AccNo: 0001654954-25-012045 Size: 39 KB